{"type":"trials","record":{"id":42045,"source_id":"clinicaltrials-gov","external_id":"NCT00390026","title":"The Avastin vs Visudyne for Neovascular AMD Study","brief_summary":"The object of the study is to compare the treatment effect of bevacizumab (Avastin), an antibody targeting vascular endothelial growth factor, with verteporfin photodynamic therapy (PDT) for patients with neovascular age-related macular degeneration, the leading cause of vision severe loss in the Western world.","overall_status":"Withdrawn","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"St. Erik Eye Hospital","enrollment":0,"countries":["Sweden"],"start_date":"2006-11-01","completion_date":"2008-11-01","last_update_date":"2024-01-31","source_url":"https://clinicaltrials.gov/study/NCT00390026","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":"Visudyne","organization":"St. Erik Eye Hospital","interventions":["Bevacizumab (Avastin)","Verteporfin photodynamic therapy (PDT)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Proportion of patients losing less than 15 letters on the ETDRS visual acuity chart. — 1 year","Proportion of patients gaining more than 15 letters on the ETDRS visual acuity chart. — 1 year","Proportion of patients losing more than 30 letters on the ETDRS visual acuity chart. — 1 year"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","source_has_results":false},"controlled_terms":["Age-related Macular Degeneration","Bevacizumab (Avastin)","Verteporfin photodynamic therapy (PDT)"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct00390026","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2006-11-01 to 2008-11-01","comparator":"Visudyne","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.911Z","intervention":["Bevacizumab (Avastin)","Verteporfin photodynamic therapy (PDT)"],"participants":0,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · DOUBLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Proportion of patients losing less than 15 letters on the ETDRS visual acuity chart. — 1 year","Proportion of patients gaining more than 15 letters on the ETDRS visual acuity chart. — 1 year","Proportion of patients losing more than 30 letters on the ETDRS visual acuity chart. — 1 year"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42045","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}